Quantgene is a team of pioneers dedicated to the mission of defeating cancer. We are oncologists, clinicians, technologists, data scientists and business innovators coming together to change the future of medicine.
Jo Bhakdi is the founder and CEO of Quantgene. His work in machine learning, sequencing technology, and DNA extraction procedures defines the cutting edge of genomic diagnostics, early disease detection, and precision medicine.
Prior to Quantgene, Jo founded i2X, an investment framework that composes low-risk Venture Capital portfolios across large numbers of technology startups. The i2X platform laid important foundations for advanced analytics in both financial and biotechnology applications, such as the Quantgene machine learning platform.
Bhakdi holds a Masters in Economics and Psychology from Tubingen University, one of Germany’s leading academic institutions, with a focus on financial theory and statistics. He kicked off his career at WPP and Omnicom, where he held Strategy and Executive Director positions.
Beyond his focus on technology and the future of medicine, Bhakdi is dedicated to bringing together the best and brightest and transforming them into pioneers, pushing the boundaries of health, life, and innovation for all.
Monika E. Hagen, MD, MBA is the Chief Medical Officer of Quantgene and a board-certified General Surgeon, specializing in bariatric surgery. Trained in Germany, Switzerland, and the United States, she has over a decade of experience as a medical doctor, academic surgeon, teacher, medical device expert, and clinical trial specialist. She also received her MBA from the University of Wales in Cardiff, UK.
Dr. Hagen is an international thought leader and lecturer in bariatric and minimally invasive surgery, as well as surgical robotic technology and its clinical applications. She is a frequent speaker at medical conferences and has published extensively on topics ranging from robotic surgery to clinical trial design to the future of medicine.
Prior to joining Quantgene and utilizing her clinical, strategic planning, and business development expertise, she has served as a regular consultant to financial, technology, medical, and biotech companies. Dr. Hagen divides her time between professional roles in Geneva, Switzerland, Silicon Valley, and Santa Monica, California.
Michele Merritt is the Vice President of Commercial Operations at Quantgene where she is responsible for launching and implementing new products in the screening and oncology markets. She has a 15+ year track record at the account, management, and executive levels in pharma, molecular diagnostics and genetic testing companies.
Michele is a leader in the field, with an impressive history at Genomic Health, Ambry Genetics, Exact Sciences and Response Genetics.
She has launched and implemented several national sales campaigns for new products like Cologuard, Oncotype DX and others. Her experience in the field comes with a deep clinical network and work history with the nation’s leading physicians and oncologists. She has a BA in Communications from the University of Illinois.
Troy Skabelund is the Interim CFO at Quantgene where he is responsible for overseeing the financial planning and growth of the company. Troy has over 20 year of experience as a CFO and financial expert for organizations of all sizes and industries, including 12 years at the Walt Disney Company.
Troy is well respected in the financial industry, with a proven track record for raising capital and driving acquisitions and exits. He started his career as a systems consultant for PWC in Seattle Washington and was a graduate of Brigham Young University (BS, MAcc).
Troy is also a CPA, CGMA, CISA, and former chapter president for the Institute of Internal Auditors.
Laura Sextro is the Senior Vice President, Operations at Quantgene where she is responsible for developing and operationalizing all areas of infrastructure, analytics, finance and strategic planning.
Laura has worked in various industries throughout her career, including non-profit and Fortune 100 companies. She was responsible for developing the business operations structure for Ambry Genetics. Her background in finance coupled with her experience in communication has given her the unique ability to understand and identify the important financial and operational elements that impact an organization’s success and communicate this in a manner that is actionable.
She is an active member of many volunteer organizations. Currently, she works with the American Red Cross as a professional rescuer instructor, Unchained At Last (the only nonprofit in the US dedicated to helping women escape or resist arranged/forced marriages and rebuild their lives) as a financial and career planning counselor, and Junior Achievement (an organization dedicated to teaching economic success courses for underprivileged children in grades K-12).
She was recently asked to joined Forbes Business Council. Laura has a BA in Business Management from the University of LaVerne.
Jennifer is responsible for Quantgene’s marketing strategy, planning and implementation across corporate, employer and product brands. She manages the marketing team and is working to build out the department structure as the company continues to grow.
Jennifer brings with her 14 years of healthcare marketing and advertising experience. She has deep expertise in strategic patient-centric marketing having worked with world-leading companies including Gilead, J&J, Merck, Sanofi and Lilly. She has also led the launch of several pharmaceutical brands including Cialis for BPH, Sanofi’s insulin Toujeo and the omni-channel support platform for Gilead’s Hepatitis C portfolio. Most recently, Jennifer held the role of Group Account Director at Wunderman Health, overseeing multiple pieces of business with a focus on data-driven marketing.
Jennifer spent nine years growing up in Tokyo Japan; an experience that has added to her understanding of diversity and nuance in her work. Jennifer has a B.A. in Psychology from Columbia University’s Barnard College.
Assistant Professor of Medicine in oncology at Stanford University. Her research focuses on systems biology and computational approaches to establish a quantitative and mechanistic understanding of cancer progression. Dr. Curtis developed an integrated experimental and computational framework to measure clinically relevant patient-specific parameters and to measure clonal dynamics during tumor progression and through therapy. She aims to develop a systematic interpretation of genotype/phenotype associations in cancer by leveraging state-of-the-art technologies and robust data integration techniques.
Dr. Ferrone is the Surgical Director of the Liver Program in the Division of General Surgery at Massachusetts General Hospital. She has 22 years of experience, and her specialties include surgical oncology and surgery. She focuses in gastrointestinal malignancies and metastatic liver disease, immunologic treatment of solid tumors and GI malignancies and primary hepatic and pancreatic cancers.
Dr. Spicer is the associate Professor of Clinical Medicine and Chief of the Division of Medical Oncology at USC Norris Comprehensive Cancer and Hospital. He chairs Keck's Institutional Review Board. He is also a medical oncology attending physician at both the LAC+USC Medical Center and the USC Norris Comprehensive Cancer Center and the General Medicine Ward Attending Physician at LAC+USC Medical Center. Dr. Spicer is the founder of Balance Pharmaceuticals based in Los Angeles.
Dr. Rosenstock is the Dean Emeritus of UCLA Fielding School of Public Health. She also serves as the Chairperson of the Board of TSO3 Inc., Professor of Health Policy and Management, and Professor of Environmental Health Sciences and Medicine at UCLA. She focuses on clinical care, health care delivery, population health, research and health and regulatory policy. She also served as Director of the National Institute for Occupational Safety and Health where she created the National Occupational Research Agenda- a framework for guiding occupational safety and health research- to identify and address pressing workplace health risk.
Associate Professor of Surgery (General Surgery) at the Stanford University Medical Center. Dr. Poultsides specializes in the removal of liver, pancreatic, and other abdominal tumors. He is currently researching outcomes analysis following multidisciplinary treatment of hepatic, pancreatic and gastrointestinal malignancies. He also developed a novel interdisciplinary research program assessing the completeness of surgical resection for pancreatic cancer. Dr. Poultsides is a recipient of the John AustinCollins, MD annual teaching award from the Stanford Surgery.
Associate Professor of Surgery at the Cleveland Clinic where he also serves as the Director of Robotic Endocrine Surgery and co-director of Liver Tumor Ablation Program. His specialties include laparoscopic and robotic liver surgery, laparoscopic liver tumor ablation, robotic surgery, conventional and minimally invasive endocrine surgery (thyroid, parathyroid, adrenal and pancreas). Dr. Berber has authored120 peer-reviewed papers and 15 book chapters. He serves on the Editorial Board of Surgical Laparoscopy and Endoscopy. He is a member of numerous surgical societies, including American College of Surgeons and serves on multiple committees.